303 related articles for article (PubMed ID: 33236917)
1. Olfactory Dysfunction in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Disease-Modifying Therapies.
Wnuk M; Drabik L; Marona M; Szaleniec J; Bryll A; Karcz P; Kolasinska J; Kolasinska M; Ziekiewicz M; Skladzien J; Popiela T; Slowik A
Ear Nose Throat J; 2022 Dec; 101(10):640-644. PubMed ID: 33236917
[TBL] [Abstract][Full Text] [Related]
2. First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study.
Maniscalco GT; Saccà F; Lanzillo R; Annovazzi P; Baroncini D; Binello E; Repice A; Perini P; Clerico M; Mataluni G; Bonavita S; La Gioia S; Gutierrez LP; Laroni A; Frau J; Cocco E; Torri Clerici V; Zarbo IR; Sartori A; Signoriello E; Rasia S; Cordioli C; Stromillo ML; Cerqua R; Pontecorvo S; Di Sapio A; Grasso R; Barone S; Lavorgna L; Barrilà C; Landi D; Russo CV; Frigeni B; Ippolito D; Turano G; Carmisciano L; Sormani MP; Signori A
Mult Scler Relat Disord; 2020 Jul; 42():102059. PubMed ID: 32208344
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis.
Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
J Neurol; 2021 Mar; 268(3):941-949. PubMed ID: 32974794
[TBL] [Abstract][Full Text] [Related]
4. Measures of Thalamic Integrity are Associated with Cognitive Functioning in Fingolimod-treated Multiple Sclerosis Patients.
Conway DS; Planchon SM; Oh SH; Nakamura K; Thompson NR; Sakaie K; Ontaneda D
Mult Scler Relat Disord; 2021 Jan; 47():102635. PubMed ID: 33260053
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
[TBL] [Abstract][Full Text] [Related]
6. Olfactory Dysfunction and Cognition in Radiologically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis.
Arici Duz O; Saatci O; Karakulak EZ; Birday E; Hanoglu L
Eur Neurol; 2021; 84(3):175-182. PubMed ID: 33831865
[TBL] [Abstract][Full Text] [Related]
7. Effect of smoking on disease activity in multiple sclerosis patients treated with dimethyl fumarate or fingolimod.
Tanaka E; Watanabe M; Fukumoto S; Masaki K; Yamasaki R; Matsushita T; Isobe N
Mult Scler Relat Disord; 2023 Feb; 70():104513. PubMed ID: 36689892
[TBL] [Abstract][Full Text] [Related]
8. Olfactory identification associates with cognitive function and the third ventricle width in patients with relapsing-remitting multiple sclerosis.
Okada K; Kakeda S; Tahara M
Mult Scler Relat Disord; 2020 Feb; 38():101507. PubMed ID: 31766000
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
[TBL] [Abstract][Full Text] [Related]
10. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
[TBL] [Abstract][Full Text] [Related]
11. Neurometabolic changes in multiple sclerosis: Fingolimod versus beta interferon or glatiramer acetate therapy.
Al-Iedani O; Lea R; Ribbons K; Ramadan S; Lechner-Scott J
J Neuroimaging; 2022 Nov; 32(6):1109-1120. PubMed ID: 35922880
[TBL] [Abstract][Full Text] [Related]
12. Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis.
Papadopoulou A; Müller-Lenke N; Naegelin Y; Kalt G; Bendfeldt K; Kuster P; Stoecklin M; Gass A; Sprenger T; Radue EW; Kappos L; Penner IK
Mult Scler; 2013 Sep; 19(10):1290-6. PubMed ID: 23459568
[TBL] [Abstract][Full Text] [Related]
13. Real-life use of oral disease-modifying treatments in Austria.
Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
Acta Neurol Scand; 2019 Jul; 140(1):32-39. PubMed ID: 30958901
[TBL] [Abstract][Full Text] [Related]
14. Stability of longitudinal DTI metrics in MS with treatment of injectables, fingolimod and dimethyl fumarate.
Alshehri A; Al-Iedani O; Koussis N; Khormi I; Lea R; Lechner-Scott J; Ramadan S
Neuroradiol J; 2023 Aug; 36(4):388-396. PubMed ID: 36395524
[TBL] [Abstract][Full Text] [Related]
15. Association between symbol digit modalities test and regional cortex thickness in young adults with relapsing-remitting multiple sclerosis.
Tao Y; XueSong Z; Xiao Y; YueZhi K; Xin W; YanPing T; Lei W; YongPing F
Clin Neurol Neurosurg; 2021 Aug; 207():106805. PubMed ID: 34280674
[TBL] [Abstract][Full Text] [Related]
16. Inclusion of the Symbol Digit Modalities Test in a revised assessment of 'no evidence of disease activity-4 (NEDA-4)' in Latin-American patients with multiple sclerosis.
Guevara C; Villa E; Diaz V; Garrido C; Martinez M; Orellana P; Alarcón P; Silva-Rosas C; Barker GJ; Kempton MJ; de Grazia J
Mult Scler Relat Disord; 2020 Jul; 42():102076. PubMed ID: 32361478
[TBL] [Abstract][Full Text] [Related]
17. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
Vermersch P; Martinelli V; Pfleger C; Rieckmann P; Alonso-Magdalena L; Galazka A; Dangond F; Phillips L
Clin Ther; 2019 Feb; 41(2):249-260.e18. PubMed ID: 30846120
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic inertia in relapsing-remitting multiple sclerosis.
Rodrigues R; Rocha R; Bonifácio G; Ferro D; Sabença F; Gonçalves AI; Correia F; Pinheiro J; Loureiro JL; Guerreiro RP; Vale J; Sá MJ; Costa A
Mult Scler Relat Disord; 2021 Oct; 55():103176. PubMed ID: 34343868
[TBL] [Abstract][Full Text] [Related]
19. Thalamic-hippocampal-prefrontal disruption in relapsing-remitting multiple sclerosis.
Kern KC; Gold SM; Lee B; Montag M; Horsfall J; O'Connor MF; Sicotte NL
Neuroimage Clin; 2015; 8():440-7. PubMed ID: 26106524
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for relapsing-remitting multiple sclerosis.
He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]